Consistent with NOS2 and COX2 inflammatory pathway cross talk in human breast cancer, a recent report finds co-expression of iNOS and COX2 predicts poor survival in breast cancer patients, and animal modeling confirms survival benefit with dual targeting of iNOS and COX262. This evidence concerns the gene NOS2 and breast cancer.